New hope for advanced cancer? first human trial of FL115 begins
NCT ID NCT06130722
First seen Jan 08, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This early-phase study tested a new drug called FL115 in 18 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Participants received FL115 weekly by IV. Researchers monitored side effects closely, especially for a reaction called cytokine release syndrome. This trial aims to see if FL115 can help control tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gabriel Cancer Center
Canton, Ohio, 44718, United States
-
HOAG Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
Moores Cancer Center at UCSD Health
San Diego, California, 92037, United States
Conditions
Explore the condition pages connected to this study.